RAB32 gene mutation tied to higher Parkinson’s risk, study finds
People who carry a specific mutation in the RAB32 gene have a higher risk of developing Parkinson’s disease, researchers…
Andrea Lobo is a Science writer at BioNews. She holds a Biology degree and a PhD in Cell Biology/Neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. She was a postdoctoral and senior researcher at the Institute for Research and Innovation in Health in Porto, in drug addiction, studying neuronal plasticity induced by amphetamines. As a research scientist for 19 years, Andrea participated in academic projects in multiple research fields, from stroke, gene regulation, cancer, and rare diseases. She authored multiple research papers in peer-reviewed journals. She shifted towards a career in science writing and communication in 2022.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
People who carry a specific mutation in the RAB32 gene have a higher risk of developing Parkinson’s disease, researchers…
Cycling indoors on a stationary bicycle for two may improve the health and well-being of people with Parkinson’s disease…
Rumble Boxing, a U.S. fitness brand, is partnering for the second year with Team Fox, the grassroots fundraising community…
The first patient has been dosed in a first-in-human trial testing Vanqua Bio’s VQ-101 as an oral therapy for…
NeuroVigil has launched its iBrain personal brain monitor — an investigational portable device that can noninvasively record the brain’s…
A five-year project funded by a National Institutes of Health (NIH) research grant totaling nearly $1.9 million will study amyloid…
Manifest Technologies has completed initial funding and a partnership with Johnson & Johnson to apply its artificial intelligence…
Produodopa (foslevodopa/foscarbidopa; also known as ABBV-951), a continuous infusion formulation of levodopa/carbidopa, will be available to advanced Parkinson’s…
Allyx Therapeutics will advance into Phase 2 clinical development of ALX-001, its investigational therapy for neurodegenerative conditions, in people…
Athira Pharma’s fosgonimeton (ATH-1017) shows promise as a therapy for neurodegenerative conditions including Parkinson’s disease, according to data presented…
Get regular updates to your inbox.